Mesorectal Excision with Lateral Lymph Node Dissection for Mid-low Rectal Cancer with Lateral Lymph Node Metastasis: Efficacy and Prognostic Analysis

Overview

Journal World J Surg Oncol

Publisher Biomed Central

Specialties General Surgery
Oncology

Date 2022 Mar 30

PMID 35351137

Authors

Sicheng Zhou

Yujuan Jiang

Jianwei Liang

Qian Liu

Affiliations

Soon will be listed here.

Abstract

Background: The aim of this study was to evaluate the efficacy of lateral pelvic lymph node (LPN) dissection (LPND) for rectal cancer patients with LPN metastasis (LPNM) and investigate the impact of LPNM on prognosis.

Methods: One hundred twenty-five matched pairs were selected and divided into the total mesorectal excision (TME) group and TME + LPND group for evaluation after propensity matching.

Results: No significant difference was observed in the 3-year local recurrence rate between the TME group and the TME + LPND group (10.7% vs 8.8%, P = 0.817); however, the rate of distant metastasis after TME + LPND was significantly higher (15.2% vs 7.2%, P = 0.044). When the mesorectal LN and LPN groups were subdivided, 3-year RFS was not significantly different between the internal LPN and N2 groups (57.1% vs. 55.3%, P = 0.613). There was no significant difference in RFS between the external group and the stage IV group (49.1% vs. 22.5%, P = 0.302), but RFS in the former group was significantly worse than that in the N2 group (49.1% vs. 55.3%, P = 0.044).

Conclusion: Although patients with suspected LPNM can achieve satisfactory local control after TME + LPND, systemic metastases are more likely to develop after surgery. Patients limited to internal iliac and obturator LN metastasis appear to achieve a survival benefit from LPND and can be regarded as regional LN metastasis. However, patients with LPNM in the external and common iliac LN metastasis have a poor prognosis that is significantly worse than that of N2 and slightly better than that of stage IV, and LPND should be carefully selected.

References

Kobayashi H, Mochizuki H, Kato T, Mori T, Kameoka S, Shirouzu K . Outcomes of surgery alone for lower rectal cancer with and without pelvic sidewall dissection. Dis Colon Rectum. 2009; 52(4):567-76. DOI: 10.1007/DCR.0b013e3181a1d994. View

Akiyoshi T, Watanabe T, Miyata S, Kotake K, Muto T, Sugihara K . Results of a Japanese nationwide multi-institutional study on lateral pelvic lymph node metastasis in low rectal cancer: is it regional or distant disease?. Ann Surg. 2012; 255(6):1129-34. DOI: 10.1097/SLA.0b013e3182565d9d. View

Hashiguchi Y, Muro K, Saito Y, Ito Y, Ajioka Y, Hamaguchi T . Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer. Int J Clin Oncol. 2019; 25(1):1-42. PMC: 6946738. DOI: 10.1007/s10147-019-01485-z. View

Fujita S, Akasu T, Mizusawa J, Saito N, Kinugasa Y, Kanemitsu Y . Postoperative morbidity and mortality after mesorectal excision with and without lateral lymph node dissection for clinical stage II or stage III lower rectal cancer (JCOG0212): results from a multicentre, randomised controlled, non-inferiority trial. Lancet Oncol. 2012; 13(6):616-21. DOI: 10.1016/S1470-2045(12)70158-4. View

Wang L, Hirano Y, Heng G, Ishii T, Kondo H, Hara K . The Significance of Lateral Lymph Node Metastasis in Low Rectal Cancer: a Propensity Score Matching Study. J Gastrointest Surg. 2020; 25(7):1866-1874. DOI: 10.1007/s11605-020-04825-x. View

Oki E, Shimokawa M, Ando K, Murata A, Takahashi T, Maeda K . Effect of lateral lymph node dissection for mid and low rectal cancer: An ad-hoc analysis of the ACTS-RC (JFMC35-C1) randomized clinical trial. Surgery. 2018; 165(3):586-592. DOI: 10.1016/j.surg.2018.08.027. View

Yokoyama S, Takifuji K, Hotta T, Matsuda K, Watanabe T, Mitani Y . Survival benefit of lateral lymph node dissection according to the region of involvement and the number of lateral lymph nodes involved. Surg Today. 2013; 44(6):1097-103. DOI: 10.1007/s00595-013-0815-y. View

Sato H, Maeda K, Maruta M . Prognostic significance of lateral lymph node dissection in node positive low rectal carcinoma. Int J Colorectal Dis. 2011; 26(7):881-9. DOI: 10.1007/s00384-011-1170-3. View

Ueno H, Mochizuki H, Hashiguchi Y, Ishiguro M, Miyoshi M, Kajiwara Y . Potential prognostic benefit of lateral pelvic node dissection for rectal cancer located below the peritoneal reflection. Ann Surg. 2007; 245(1):80-7. PMC: 1867942. DOI: 10.1097/01.sla.0000225359.72553.8c. View

10.

Yagi R, Shimada Y, Kameyama H, Tajima Y, Okamura T, Sakata J . Clinical Significance of Extramural Tumor Deposits in the Lateral Pelvic Lymph Node Area in Low Rectal Cancer: A Retrospective Study at Two Institutions. Ann Surg Oncol. 2016; 23(Suppl 4):552-558. PMC: 5035319. DOI: 10.1245/s10434-016-5379-9. View

11.

Numata M, Tamagawa H, Kazama K, Kawahara S, Sawazaki S, Aoyama T . Lateral lymph node dissection for mid-to-low rectal cancer: is it safe and effective in a practice-based cohort?. BMC Surg. 2021; 21(1):51. PMC: 7818758. DOI: 10.1186/s12893-021-01053-1. View

12.

Nagasaki T, Akiyoshi T, Fujimoto Y, Konishi T, Nagayama S, Fukunaga Y . Preoperative Chemoradiotherapy Might Improve the Prognosis of Patients with Locally Advanced Low Rectal Cancer and Lateral Pelvic Lymph Node Metastases. World J Surg. 2016; 41(3):876-883. DOI: 10.1007/s00268-016-3748-y. View

13.

Ishihara S, Kawai K, Tanaka T, Kiyomatsu T, Hata K, Nozawa H . Oncological Outcomes of Lateral Pelvic Lymph Node Metastasis in Rectal Cancer Treated With Preoperative Chemoradiotherapy. Dis Colon Rectum. 2017; 60(5):469-476. DOI: 10.1097/DCR.0000000000000752. View

14.

Anania G, Davies R, Arezzo A, Bagolini F, DAndrea V, Graziosi L . Rise and fall of total mesorectal excision with lateral pelvic lymphadenectomy for rectal cancer: an updated systematic review and meta-analysis of 11,366 patients. Int J Colorectal Dis. 2021; 36(11):2321-2333. PMC: 8505280. DOI: 10.1007/s00384-021-03946-2. View

15.

Fujita S, Mizusawa J, Kanemitsu Y, Ito M, Kinugasa Y, Komori K . Mesorectal Excision With or Without Lateral Lymph Node Dissection for Clinical Stage II/III Lower Rectal Cancer (JCOG0212): A Multicenter, Randomized Controlled, Noninferiority Trial. Ann Surg. 2017; 266(2):201-207. DOI: 10.1097/SLA.0000000000002212. View